Lexaria Bioscience CEO Richard Christopher summarizes details from $LEXX human clinical trials evaluating #DehydraTECH & GLP1 agonists along with the technology’s key benefits.
#LexariaBioscience #LexariaDelivery #NextGenDrugDelivery #OralDeliveryTech #OralPeptideDelivery #GLP1Therapy #GLP1Agonist